Head-To-Head Review: Integra LifeSciences (NASDAQ:IART) & Sight Sciences (NASDAQ:SGHT)

Sight Sciences (NASDAQ:SGHT) and Integra LifeSciences (NASDAQ:IART) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.

Volatility & Risk

Sight Sciences has a beta of 2.38, suggesting that its share price is 138% more volatile than the S&P 500. Comparatively, Integra LifeSciences has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500.

Insider and Institutional Ownership

55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 84.8% of Integra LifeSciences shares are owned by institutional investors. 30.4% of Sight Sciences shares are owned by insiders. Comparatively, 3.8% of Integra LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Sight Sciences and Integra LifeSciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-46.83%	-52.34%	-28.49%
Integra LifeSciences	-30.15%	17.42%	5.00%

Valuation and Earnings

This table compares Sight Sciences and Integra LifeSciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sight Sciences	$77.36 million	3.31	-$38.43 million	($0.71)	-6.62
Integra LifeSciences	$1.64 billion	0.88	-$516.47 million	($6.46)	-2.87

Sight Sciences has higher earnings, but lower revenue than Integra LifeSciences. Sight Sciences is trading at a lower price-to-earnings ratio than Integra LifeSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Sight Sciences and Integra LifeSciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1	3	5	0	2.44
Integra LifeSciences	2	4	1	0	1.86

Sight Sciences currently has a consensus price target of $8.25, indicating a potential upside of 75.53%. Integra LifeSciences has a consensus price target of $18.33, indicating a potential downside of 1.22%. Given Sight Sciences’ stronger consensus rating and higher probable upside, equities analysts plainly believe Sight Sciences is more favorable than Integra LifeSciences.

Summary

Sight Sciences beats Integra LifeSciences on 8 of the 14 factors compared between the two stocks.

About Sight Sciences

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.